LDS/Medical Tests/Lupus Anticoagulants

Lupus Anticoagulants

Lupus anticoagulants are antibodies (immunoglobulins) that inhibit phospholipid dependent coagulation or blood clotting. These antibodies are not specific for any single coagulation factor, but recognize phospholipid and glycoprotein epitopes, thereby inhibiting in vitro formation of phospholipid dependent, activated coagulation factor complexes. Lupus anticoagulants are a common cause of prolonged activated partial thromboplastin times (APTT), the prothrombin time (PT), and dilute Russell Viper Venom Test (dRVVT). Circulating lupus-like anticoagulants are recognized as a major cause of both venous and arterial thromboembolic events, often encountered in settings such as recurrent abortion and pregnancy complications and fetal loss, deep vein thrombosis, and arterial thrombosis. In addition, Lupus anticoagulants may be associated with autoimmune diseases, drugs (including procainamide, quinidine, chlorpromazine, hydralazine, antibiotics, and phenytoin), infections, lymphoproliferative disorders, and malignancy. Lupus anticoagulants is a panel that includes anticardiolipin antibody, PTT, PT and dilute Russell Viper Venom (dRVVT) for screening followed by mixing studies if PTT is positive.

Anti-Cardiolipin Antibody
Cardiolipins are phospholipids that play a vital role in cellular function such as osmosis and the transfer of metabolites across the plasma membrane. In addition to these function cardiolipins play an important role in blood clotting. When antibodies to these cardiolipins are present, they are unable to function properly and disease can develop. Anticardiolipin antibodies are seen in various disease states such as Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS). Anticardiolipin antibodies when present can indicate disorders such as vascular thrombosis, thrombocytopenia, and hemolytic anemia. They are also implicated in recurrent miscarriages, premature birth, and preeclampsia.

PT and aPTT
PT and PTT are used to evaluate patients who are suspected to have increased risk of clotting or bleeding-related diseases (hyper- or hypocoagulation). These tests measure the amount of time it takes to form a fibrin clot in the blood using the "intrinsic" and "extrinsic" coagulation pathways. The activated Partial Thromboplastin Time (aPTT) and Prothrombin Time (PT) are most often used to screen for an increased clotting time (hypocoagulation).

Dilute Russell Viper Venom (dRVVT)
dRVVT is a clotting test useful for patients that exhibit a prolonged PT with a normal aPTT and TT. In this clinical setting a normal RVVT would suggest a deficiency of Factor VII. RVVT is also used in detection of antiphospholipid antibodies (so-called lupus anticoagulant, LAC). It should be noted that this anticoagulant, detected in vitro, may be associated with vascular thrombosis and pregnancy-related morbidity in vivo.

  • Evaluation of hypercoagulable states (in bleeding disorders)
  • As an aid in diagnosis of thromboembolism
  • As an aid in diagnosis of recurrent abortion (recurrent miscarriage) and other pregnancy complications
  • As an aid in diagnosis of thrombocytopenia or prolonged PTT

Increased in:

  • Recurrent Arterial and Venous Thrombosis
  • Deep vein thrombosis
  • Stroke and myocardial and visceral infarctions
  • Antiphospholipid antibody syndrome
  • Prolonged clotting times (PTT, dRVVT and PT)
  • Thrombocytopenia
  • Pregnancy complication and abortion
  • Fetal Growth Retardation
  • Preeclampsia
  • Coombs Positive Hemolytic Anemia
  • Autoimmune disease
  • In some drugs (including procainamide, quinidine, chlorpromazine, hydralazine, antibiotics, and phenytoin)
  • In some infections (sepsis)
  • Cutaneous Necrosis

Cardiolipin IgG: <20 GPL

Cardiolipin IgA: <12 APL

Cardiolipin IgM: <20 MPL

PT: 10-12 seconds

aPTT: 20-25 seconds

dRVVT: 24–37 seconds


 

 

Anticardiolipins are detected by serology (ELISA and immunoassay); PTT, PT and dilute Russell Viper Venom (dRVVT) are performed using coagulation methods (see each individual test for more).

Plasma

Platelet-poor Plasma (Light blue top, Citrate). 4 mL minimum. Freeze immediately at -40C if possible, and maintain frozen until tested.
Patient should not be on Coumadin or heparin.

Stability

  • Ambient - Unacceptable.
  • Refrigerated - Unacceptable.
  • Frozen - 14 days.
Antiphospholipid Antibody, Specific factor assays as indicated, Mixing Studies, Prekallikrein, von Willebrand Factor assay, Lupus Anticoagulant, Anti-Beta 2 Glycoprotein, Plasminogen Activator Inhibitor 1.
Up to 7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login